Piper Sandler Reiterates Overweight Rating on Savara (SVRA)

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $16.00 price target on Savara (NASDAQ: SVRA).

The analyst commented, "Last week we hosted SVRA for an investor dinner before it enters a quiet period as we await the highly de-risked IMPALA-2 topline data readout, on track for end of June. As such, we walked away from the dinner with continued bullish sentiment about the PoS of IMPALA-2 to drive significant share gains. Most importantly, not only are we confident on study success, but it was clear to us that SVRA will be providing rich data to support the market opportunity in aPAP not only at topline, but thereafter in 2H24. This includes both market research data, unmet need, and outreach that makes us continue to believe this is one of the few names in biotech with low clinical risk, and high opportunity to drive significant share gains."

For an analyst ratings summary and ratings history on Savara click here. For more ratings news on Savara click here.

Shares of Savara closed at $3.96 yesterday.

You May Also Be Interested In

• Backblaze Inc (BLZE) PT Raised to $14 at Needham
• FedEx (FDX) PT Lowered to $350 at UBS on Lowered EPS Estimates
• Clearway Energy Inc. (CWEN) PT Raised to $45 at UBS After Model Update